Login to myESAIC Membership


The ESAIC is dedicated to supporting professionals in anaesthesiology and intensive care by serving as the hub for development and dissemination of valuable educational, scientific, research, and networking resources.



The ESAIC hosts the Euroanaesthesia and Focus Meeting congresses that serve as platforms for cutting-edge science and innovation in the field. These events bring together experts, foster networking, and facilitate knowledge exchange in anaesthesiology, intensive care, pain management, and perioperative medicine. Euroanaesthesia is one of the world’s largest and most influential scientific congresses for anaesthesia professionals. Held annually throughout Europe, our congress is a contemporary event geared towards education, knowledge exchange and innovation in anaesthesia, intensive care, pain and perioperative medicine, as well as a platform for immense international visibility for scientific research.


Professional Growth

The ESAIC's mission is to foster and provide exceptional training and educational opportunities. The ESAIC ensures the provision of robust and standardised examination and certification systems to support the professional development of anaesthesiologists and to ensure outstanding future doctors in the field of anaesthesiology and intensive care.



The ESAIC aims to advance patient outcomes and contribute to the progress of anaesthesiology and intensive care evidence-based practice through research. The ESAIC Clinical Trial Network (CTN), the Academic Contract Research Organisation (A-CRO), the Research Groups and Grants all contribute to the knowledge and clinical advances in the peri-operative setting.

Learn more about the ESAIC Clinical Trial Network (CTN) and the associated studies.


EU Projects

The ESAIC is actively involved as a consortium member in numerous EU funded projects. Together with healthcare leaders and practitioners, the ESAIC's involvement as an EU project partner is another way that it is improving patient outcomes and ensuring the best care for every patient.


Patient Safety

The ESAIC aims to promote the professional role of anaesthesiologists and intensive care physicians and enhance perioperative patient outcomes by focusing on quality of care and patient safety strategies. The Society is committed to implementing the Helsinki Declaration and leading patient safety projects.



To ESAIC is committed to implementing the Glasgow Declaration and drive initiatives towards greater environmental sustainability across anaesthesiology and intensive care in Europe.



The ESAIC works in collaboration with industry, national societies, and specialist societies to promote advancements in anaesthesia and intensive care. The Industry Partnership offers visibility and engagement opportunities for industry participants with ESAIC members, facilitating understanding of specific needs in anaesthesiology and in intensive care. This partnership provides resources for education and avenues for collaborative projects enhancing science, education, and patient safety. The Specialist Societies contribute to high-quality educational opportunities for European anaesthesiologists and intensivists, fostering discussion and sharing, while the National Societies, through NASC, maintain standards, promote events and courses, and facilitate connections. All partnerships collectively drive dialogue, learning, and growth in the anaesthesiology and intensive care sector.



Guidelines play a crucial role in delivering evidence-based recommendations to healthcare professionals. Within the fields of anaesthesia and intensive care, guidelines are instrumental in standardizing clinical practices and enhancing patient outcomes. For many years, the ESAIC has served as a pivotal platform for facilitating continuous advancements, improving care standards and harmonising clinical management practices across Europe.



With over 40 years of publication history, the EJA (European Journal of Anaesthesiology) has established itself as a highly respected and influential journal in its field. It covers a wide range of topics related to anaesthesiology and intensive care medicine, including perioperative medicine, pain management, critical care, resuscitation, and patient safety.



Becoming a member of ESAIC implies becoming a part of a vibrant community of nearly 8,000 professionals who exchange best practices and stay updated on the latest developments in anaesthesiology, intensive care and perioperative medicine. ESAIC membership equips you with the tools and resources necessary to enhance your daily professional routine, nurture your career growth, and play an active role in advancing anaesthesiology, intensive care and perioperative medicine.

Membership opportunities
at the ESAIC

Congress Newsletter 2021

EA21 Newsletter: Successful heart transplant in 31-year-old Covid patient

  • It was decided that the operation, one of the first in the world, was his best chance of survival
  • “It is through pushing boundaries like these that discoveries – and medical advances – are made,” says his doctor

In the first of our abstract watch articles this year, Doctors in Brazil describe a heart transplant in a young COVID-19 patient, in a case report being presented at this years Euroanaesthesia.

More than 110,000 heart transplants have been performed around the world since Christiaan Barnard performed the first procedure in 1968. Doctors, however, remain concerned about carrying out transplants on patients carrying new diseases. Covid is no exception, with little known about the outcome of heart transplants in patients who have had the virus.

The patient, a 31-year-old man, had the procedure at the Hospital Israelita Albert Einstein in Sao Paulo in May 2021, while he was still recovering from Covid.

The transplant, one of the first cases of its kind anywhere in the world, illustrates that heart transplants can be successful after severe Covid infections, says Dr Eduardo Mocsári who, along with fellow anaesthesiologists Thales Tedoldi, Jose Mateus Costa, Marina Cordeiro and Luiz Guilherme Villares da Costa, was part of the team who carried out the op.

The patient had been diagnosed with familial inherited cardiomyopathy, an inherited heart condition, two years earlier. His health had then rapidly deteriorated and he developed heart failure, in which the heart is unable to pump blood around the body properly.

He was listed for a heart transplant after his heart failure continued to worsen, despite being treated with high doses of inotropic drugs and an LVAD (a surgically implanted mechanical pump).

By the time of his transplant, he had a left ventricular ejection fraction (a measure of how well the heart is pumping blood) of 15%. A normal result is 50 to 70%.

He tested positive for COVID-19 during admission and the procedure was postponed.  The patient went on to develop a fever and respiratory failure, for which he was put on a ventilator. This was followed by cardiogenic shock (a life-threatening condition in which the heart suddenly can’t pump enough blood to meet your body’s needs), for which he was put on ECMO (a machine that replaces the function of the heart and lungs).

His heart continued to deteriorate and, after his respiratory symptoms started to improve, it was decided that although he hadn’t completely recovered from Covid, the transplant gave him the best chance of survival.

The transplant was carried out on 4 May 2021, 42 days after he was diagnosed with Covid.

The patient was testing negative for Covid at that point but still required a ventilator and ECMO and the team wore full PPE during the transplant.

The five-hour operation went smoothly and, with his new heart working well, the patient no longer needed a mechanical heart pump. He then spent 20 days in intensive care and was discharged from the hospital 66 days after his transplant.

He developed one complication, necrosis of his toes, which led to some of his toes being amputated and will take immunosuppressant drugs for life to prevent the new organ from being rejected.

Dr Mocsári says that although heart transplant is the gold standard surgical treatment for heart failure that isn’t responding to other therapies, COVID-19 adds an extra layer of risk. As a result, doctors have been hesitant about carrying out heart transplants on Covid patients.

He adds: “Heart transplantation after COVID-19 infection is something new and we are still learning about the risks and complications.

“In this case, the patient hadn’t fully recovered and we were concerned his Covid would worsen.  Several studies have indicated that transplant patients are at greater risk of more severe Covid and of dying from the disease.*

“But, as his heart was still deteriorating, we decided that the transplant gave him the best chance of survival.

“As this case illustrates, despite there being few reports in the literature, heart transplantation in patients who have had severe COVID-19 can have a favourable outcome.

“There are situations, where despite all the unknowns, a transplant is the best option. It is through pushing boundaries like these that discoveries – and medical advances – are made.”

Currently, the patient is hospitalized due to an abdominal infection but has responded well to treatment and is on his way to being discharged. In addition to immunosuppressants (Tacrolimus and Mycophenolate), he is also taking antibiotics.

Author Dr Eduardo Mocsári, Hospital Israelita Albert Einstein, Sao Paulo, Brazil can be contacted as follows E) eduardoferro03@gmail.com

For the full abstract click here

For the full poster click here


Read More of our special newsletter covering our virtual congress.